IceCure Medical has partnered with West Cancer Center & Research Institute as the first U.S. clinical site for its ChoICE Study, a post-marketing trial of ProSense® cryoablation for treating low-risk breast cancer. The study will enroll up to 400 patients across 30 sites to collect real-world data following FDA approval in October 2025. This effort aims to expand clinical use and patient access to minimally invasive cryoablation as an alternative to surgery for eligible patients aged 70 and above with small, low-risk tumors. The dual role of study and commercial sites will facilitate broader treatment availability beyond the trial.
Bitcoin's price hovered near $63,069 following a 47% decline over the past year, with key support at $61,126 and resistance at $63,517. Michael Saylor highlighted that Strategy's STRC preferred stock, part of its digital credit products, returned 9% ...
Algorand's v5.0.0 upgrade has reached 90% node support and will activate soon after its cooldown period, marking the largest update since staking rewards launched. This upgrade introduces native Falcon-1024 post-quantum accounts, expanding quantum-re...
Since its 2021 reorganization, APA Corporation has prioritized reducing debt, cutting costs, and consolidating its portfolio rather than rapid production growth. Key moves include acquiring Callon Petroleum for $4.5 billion and increasing cost reduct...
Bitcoin closed the week down 2.7% at around $62,990, with spot Bitcoin ETFs reversing strong inflows into outflows and XRP briefly falling below $1 due to a cross-chain bridge exploit. Despite stable prices, significant structural shifts occurred: Go...
Bitcoin is currently exhibiting a rare long-term oversold condition on two key technical indicators, suggesting the bearish trend may be nearing exhaustion. Analyst Katie Stockton highlights this alongside improving momentum, which could indicate the...
